Cytokine expression in subjects with

Published
February 28, 2024
Journal
Frontiers in cellular and infection microbiology
PICOID
0eaac950
DOI
Citations
2
Keywords
Crohn’s disease, MAP, autoimmune disease, bacteremia, inflammatory bowel disease (IBD)
Copyright
Copyright © 2024 Kuenstner, Xu, Bull, Foddai, Grant, Naser, Potula, Zhang, Shafran, Akhanli, Khaiboullina and Kruzelock.
Patients/Population/Participants

CD patients, non-CD controls

Intervention

MAP positive blood cultures

Comparison

cytokine expression patterns in MAP culture positive CD patients and patients with Tuberculosis

Outcome

increased IL-17, IFNγ and TNFα

Abstract

P
I
C
O

1) Culture The Temple University/Abilene Christian University (TU/ACU) study had a prospective case control design with 201 subjects including 61 CD patients and 140 non-CD controls. The culture methods included MGIT, TiKa and Pozzato broths, and were deemed MAP positive, if IS900 PCR positive. A phage amplification assay was also performed to detect MAP. Cytokine analysis of the TU/ACU samples was performed using Simple Plex cytokine reagents on the Ella ELISA system. Statistical analyses were done after log transformation using the R software package. The meta-analysis combined three studies. Most subjects had MAP positive blood cultures by one or more methods in 3 laboratories. In our cytokine study comparing CD to non-CD controls, IL-17, IFNγ and TNFα were significantly increased in CD, but IL-2, IL-5, IL-10 and GM-CSF were not increased. In the meta-analysis, IL-6, IL-8 and IL-12 were significantly increased in the CD patients. Most subjects in our sample had MAP infection and 8 of 9 subjects remained MAP positive one year later indicating persistent infection. While not identical, cytokine expression patterns in MAP culture positive CD patients in the TU/ACU study showed similarities (increased IL-17, IFNγ and TNFα) to patterns of patients with Tuberculosis in other studies, indicating the possibilities of similar mechanisms of pathogen infection and potential strategies for treatment.

Similar article map

CEO: Hwi-yeol YunCOO: Jung-woo ChaeCTO: Sangkeun Jung
Location: 204, W6, Chungnam National University, 99, Daehak-ro, Yuseong-gu, Daejeon, Republic of Korea
Tel: 042-821-7328E-mail: webmaster@lilac-co.kr
Copyright © 2024 by LiLac. All Rights Reserved.